Literature DB >> 2041383

(131I)meta-iodobenzylguanidine scintigraphy and selective venous catheterization after thyroidectomy for medullary thyroid carcinoma.

G Lupoli1, G Lombardi, N Panza, B Biondi, G Pacilio, S Lastoria, M Salvatore.   

Abstract

Fifteen patients with medullary carcinoma of the thyroid (MCT), who had persistently elevated levels of serum calcitonin (CT) and carcinoembryonic antigen (CEA) after total thyroidectomy, were studied in order to localize the sites of the recurrent disease. Routine diagnostic examinations, including ultrasonography (US) and computed axial tomography (CAT), were carried out in all the cases. Scintigraphy with radio-iodinated metaiodobenzylguanidine ((131I)-MIBG) was performed in 13 cases; selective venous catheterization (SVC) to reveal a gradient of CT levels was performed in 12 cases. Ten patients underwent both (131I)-MIBG scintigraphy and SVC. US and CAT revealed the sites of recurrent tumor in only 4 out of the total 15 patients. SVC in basal conditions showed the presence of small metastases in 2 cases, and after intravenous stimulus with pentagastrin in 4 others. The MIBG scan showed metastatic foci of sporadic MCT in 2 patients, residual medullary thyroid tissue in 4 others, and a pheochromocytoma in a previously undiagnosed patient with Sipple's syndrome. More particularly, MIBG scan and SVC showed the localization of residual or metastatic tumor in 10 cases. In all 10 cases, results of the MIBG scan and SVC were confirmed as true positive by subsequent surgery and histopathologic examination.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2041383     DOI: 10.1007/bf02988565

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  22 in total

1.  Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP--an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid.

Authors:  S E Clarke; C R Lazarus; P Wraight; C Sampson; M N Maisey
Journal:  J Nucl Med       Date:  1988-01       Impact factor: 10.057

2.  The role of technetium-99m pentavalent DMSA in the management of patients with medullary carcinoma of the thyroid.

Authors:  S E Clarke; C Lazarus; R Mistry; M N Maisey
Journal:  Br J Radiol       Date:  1987-11       Impact factor: 3.039

3.  Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma.

Authors:  N Panza; G Pacilio; L Campanella; G Peluso; C Battista; A Amoriello; W Utech; C Vacca; G Lombardi
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

4.  Radioimmunoassay for calcitonin in medullary thyroid carcinoma.

Authors:  L J Deftos
Journal:  JAMA       Date:  1974-01-28       Impact factor: 56.272

5.  Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine.

Authors:  J Treuner; U Feine; D Niethammer; W Müller-Schaumburg; J Meinke; E Eibach; R Dopfer; T Klingebiel; S Grumbach
Journal:  Lancet       Date:  1984-02-11       Impact factor: 79.321

6.  131I-MIBG and medullary carcinoma of the thyroid.

Authors:  J M Connell; T E Hilditch; A Elliott; P F Semple
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

7.  Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma.

Authors:  L Von Moll; A J McEwan; B Shapiro; J C Sisson; M D Gross; R Lloyd; E Beals; W H Beierwaltes; N W Thompson
Journal:  J Nucl Med       Date:  1987-06       Impact factor: 10.057

8.  Medullary thyroid carcinoma: importance of serial serum calcitonin measurement.

Authors:  A V Stepanas; N A Samaan; C S Hill; R C Hickey
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

9.  Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study.

Authors:  J L Baulieu; D Guilloteau; M J Delisle; R Perdrisot; P Gardet; N Delépine; F Baulieu; J L Dupont; J N Talbot; G Coutris
Journal:  Cancer       Date:  1987-11-01       Impact factor: 6.860

10.  Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl guanidine.

Authors:  G J Poston; A M Thomas; D W Macdonald; D Karvounaris; B L Henderson; P George; J A Lynn; J P Lavender
Journal:  Nucl Med Commun       Date:  1986-04       Impact factor: 1.690

View more
  1 in total

1.  The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.

Authors:  Zairong Gao; Hans J Biersack; Samer Ezziddin; Timur Logvinski; Rui An
Journal:  J Cancer Res Clin Oncol       Date:  2004-08-05       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.